Seres Therapeutics, Inc. 8-K

What Happened

• Seres Therapeutics (MCRB) filed an 8‑K reporting two material agreements amended in early June 2026. On June 2, 2026 the company and Société des Produits Nestlé S.A. (SPN) agreed to terminate SPN’s obligations for two future sales milestones ($125M at $400M sales and $150M at $750M sales) and eliminate associated milestone interest payments. In exchange, SPN will pay Seres a one‑time Milestone Termination Payment of $25.0 million payable in two equal installments of $12.5M on July 1, 2026 and October 1, 2026.
• On June 4, 2026 Seres entered a First Amendment to Lease for its Cambridge, MA space (101 CambridgePark Drive). The company surrendered about 45,832 rentable sq ft (leaving 36,882 sq ft), extended the remaining lease term from March 31, 2033 to December 31, 2036, reduced base rent to $79.70 per rentable sq ft/year (effective May 1, 2026), and cut its building operating cost share from 51.36% to 24.25%. The amendment also defers eight months of rent into a lump sum due January 4, 2027 and permits the landlord to draw an existing $6.3M letter of credit that Seres records as restricted cash.

Key Details

• $25.0M Milestone Termination Payment from SPN, paid in two $12.5M installments (7/1/2026 and 10/1/2026).
• Eliminated contingent milestone obligations of $125.0M (at $400M sales) and $150.0M (at $750M sales) plus milestone interest.
• Lease change: surrendered ~45,832 sq ft; remaining 36,882 sq ft lease extended to 12/31/2036; base rent reduced to $79.70/sq ft/year; estimated aggregate decrease of ~$33.9M in lease payments.
• Cash/near‑term payments tied to lease amendment: $4.5M termination fee due on execution; up to $5.2M deferred payment (cash or letter of credit) due by 1/4/2027 (includes $2.0M to cover May–Dec 2026 rent and $3.2M additional termination payment); landlord may draw $6.3M existing letter of credit (restricted cash).

Why It Matters

• Near‑term liquidity: the $25M from Nestlé provides a one‑time cash inflow in 2 installments and the lease changes substantially lower future rent obligations (estimated ~$33.9M reduction), which can improve cash burn profile.
• Trade‑off for future upside: by terminating the two sales milestones and related interest, Seres gives up potential large contingent milestone receipts ($125M and $150M) tied to future product sales in exchange for immediate cash certainty.
• Cash reporting: the landlord draw of a $6.3M letter of credit is recorded as restricted cash and is excluded from Seres’ cash runway projections, and the company has near‑term cash obligations related to lease termination and deferred rent payments due early January 2027.